HBM Healthcare Investments reported beneficial ownership of 80,971,680 Chemomab Therapeutics ordinary shares, equal to 12.5%, and elected to exercise pre-funded warrants. The move matters because HBM said the Warrant exercise is intended to fulfill its voting obligations under a Shareholder Support Agreement.

Key Highlights

  • HBM sent Chemomab formal notice of its warrant election on September 7, 2026.
  • Each ADS held by HBM represents 80 Chemomab ordinary shares.
  • Voting and Investment authority rests with HBM’s board, whose six members have no individual power over the holdings.

HBM Elects Pre-Funded Warrant Exercise

HBM sent formal notice of its election to Chemomab (NASDAQ: CMMB) on September 7, 2026. The investor holds American Depositary Shares, with each ADS representing 80 ordinary shares without par value. Beneficial ownership is presented in ordinary shares rather than ADSs. Jean-Marc LeSieur signed the document for HBM as managing director on September 9, 2026.

Shareholder Support Agreement Sets Purpose

The warrant election is tied to HBM’s stated voting obligations under the Shareholder Support Agreement. The update supplements information previously provided in the Schedule 13D filed on July 16, 2026, while leaving the other previously reported information unchanged except where specifically amended. HBM’s reported position is calculated using ordinary shares, while the securities held by the investor are ADSs. The document identifies Chemomab ordinary shares as the registered securities and uses the ADS CUSIP because no CUSIP is assigned to the ordinary shares.